Safety Study of Subcutaneously Administered PL-3994 in Subjects With Controlled Hypertension
Status:
Completed
Trial end date:
2008-07-01
Target enrollment:
Participant gender:
Summary
The objective of this study is to evaluate the safety, tolerability, and pharmacokinetics of
subcutaneous (SC) PL-3994, relative to placebo in subjects with controlled hypertension.
Including in this evaluation is the effect PL3994 has on blood pressure.